GlassScriptPhysician profile
Lauren Lambeth
NPI 1053738054
$4,219.50
in general payments reported to CMS, 2019-2025
45 companies · $882 in 2025
The $882 reported for 2025 was more than what 85% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $730 · 2022: $390 · 2023: $912 · 2024: $1,305 · 2025: $882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,099.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,613.75 | 2021-2025 | |
| Novo Nordisk INC | $464.71 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Galderma Laboratories, L.P. | $259.35 | 2024 | Dysport |
| Novartis Pharmaceuticals Corporation | $191.14 | 2021-2023 | |
| Glaxosmithkline, LLC. | $152.86 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $125.84 | 2023-2024 | Rexulti |
| Lilly USA, LLC | $106.02 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Ironwood Pharmaceuticals, INC | $87.90 | 2021-2023 | Linzess |
| Biohaven Pharmaceuticals, INC. | $82.73 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.52 | 2021-2024 | Trulance, Xifaxan |
| Amgen INC. | $81.85 | 2023-2024 | Repatha, Otezla |
| Pfizer INC. | $80.34 | 2021-2024 | |
| Noven Therapeutics, LLC | $76.06 | 2023-2024 | Xelstrym |
| Teva Pharmaceuticals USA, INC. | $62.93 | 2021-2024 | Austedo Xr |
| Astellas Pharma US INC | $61.42 | 2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Lambeth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.